Hypoxia imaging with PET: Which tracers and why?

Nuclear Medicine Communications

Volumn 33, Issue 3, 2012, Pages 217-222

  Chia, Kazumi ^a   Fleming, Ian N ^b   Blower, Philip J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETANIDAZOLE F 18; TRACER; UNCLASSIFIED DRUG;

HUMAN; HYPOXIA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SOLID TUMOR;

ANOXIA; HUMANS; MEDICAL ONCOLOGY; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 84856093271     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834eacb7     Document Type: Review

References (46)

1. Semenza GL. Life with oxygen. Science 2007; 318: 62-64. (Pubitemid 47538005)
2. Handley MG, Medina RA, Nagel E, Blower PJ, Southworth R. PET imaging of cardiac hypoxia: opportunities and challenges. J Mol Cell Cardiol 2011; 640-650.
3. Takasawa M, Moustafa RR, Baron J-C. Applications of nitroimidazole in vivo hypoxia imaging in Ischemic Stroke. Stroke 2008; 39: 1629-1637.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer [Review] 2003; 3: 721-732. (Pubitemid 37328811)
5. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8: 967-975.
6. Thomlinson R, Gray L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; IX: 539-549.
7. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 6, Illustrated ed. Lippincott Williams & Wilkins; 2006.
8. Steel GG. Basic clinical radiobiology. 3 ed. London: Arnold; 2002.
9. Matsumoto S, Yasui H, Mitchell JB, Krishna MC. Imaging cycling tumor hypoxia. Cancer Res 2010; 70: 10019-10023.
10. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors- experimentaltechniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10: 695-712. (Pubitemid 14084223)
11. Teicher BA, Lazo JS, Sartorelli AC. Classification of anti-neoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor-cells. Cancer Res 1981; 41: 73-81. (Pubitemid 11218796)
12. Koch CJ, Evans SM. Cysteine concentrations in rodent tumors: unexpectedly high values may cause therapy resistance. Int J Cancer 1996; 67: 661-667. (Pubitemid 26300983)
13. Kim Y, Lin Q, Glazer PM, Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 2009; 9: 425-434.
14. Søvik Å , Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys 2009; 73: 650-658.
15. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007; 25: 4066-4074. (Pubitemid 47492951)
16. Hoskin PJ, Rojas AM, SrM Bentzen, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010; 28: 4912-4918.
17. Kaanders JH, Pop LA, Marres HA, Bruaset I, van den Hoogen FJ, Merkx MA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002; 52: 769-778. (Pubitemid 34158740)
18. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a Phase III Trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28: 2989-2995.
19. Ang KK. More lessons learned from the suffocation of hypoxia. J Clin Oncol 2010; 28: 2941-2943.
20. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007; 9: 1221-1236.
21. Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular imaging of hypoxia. J Nucl Med 2011; 52: 165-168, [Epub 13 January 2011].
22. Tsai AG, Johnson PC, Intaglietta M. Oxygen gradients in the microcirculation. Physiol Rev 2003; 83: 933-963. (Pubitemid 36828928)
23. Evans RG, Gardiner BS, Smith DW, O'Connor PM. Intrarenal oxygenation: unique challenges and the biophysical basis of homeostasis. Am J Physiol Renal Physiol 2008; 295: F1259-F1270.
24. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-276. (Pubitemid 32219813)
25. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells-in vitro. Radiat Res 1990; 122: 301-308. (Pubitemid 20214420)
26. 18F]Fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999; 40: 1072-1079. (Pubitemid 29269230)
27. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40: 177-183. (Pubitemid 29044189)
28. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl)acetamide]- analysis of drug adducts by fluorescent-antibodies vs bound radioactivity. Br J Cancer 1995; 72: 869-874.
29. Hall EJ. Radiobiology for the radiologist. 1st ed. Harper and Row; 1973.
30. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62. (Pubitemid 40093472)
31. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14: 198-206. (Pubitemid 38903223)
32. Liu J, Hajibeigi A, Ren G, Lin M, Siyambalapitiyage W, Liu Z, et al. Retention of the radiotracers-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression. J Nucl Med 2009; 50: 1332-1339.
33. Lee N, Nehmeh S, Schoeder H, Fury M, Chan K, Ling CC, et al. Prospective trial incorporating pre-/mid-treatment [F-18]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 101-108.
34. Tribius S, Ihloff AS, Rieckmann T, Petersen C, Hoffmann M. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett 2011; 304: 71-79.
35. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155-1160. (Pubitemid 27339632)
36. Michalski M, Chen X. Molecular imaging in cancer treatment. Eur J Nucl Med Mol Imaging 2011; 38: 358-377.
37. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol [Article] 2005; 32: 623-630. (Pubitemid 40981818)
38. O'Donoghue JA, Zanzonico P, Pugachev A, Wen BX, Smith-Jones P, Cai SD, et al. Assessment of regional tumor hypoxia using F-18-fluoromisonidazole and Cu-64(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po-2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005; 61: 1493-1502. (Pubitemid 40470433)
39. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent Cu-64 (II)-diacetyl-bis(N-4-methylthiosemicarbazone). J NuclMed 2006; 47: 989-998. (Pubitemid 46939952)
40. Bentzen L, Keiding S, Nordsmark M, Falborg L, Hansen SB, Keller J, et al. Tumour oxygenation assessed by F-18-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003; 67: 339-344. (Pubitemid 36831089)
41. Doss M, Zhang JJ, Belanger MJ, Stubbs JB, Hostetler ED, Alpaugh K, et al. Biodistribution and radiation dosimetry of the hypoxia marker (18)F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun 2010; 31: 1016-1024.
42. Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30: 607-611. (Pubitemid 36559841)
43. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996; 23: 957-980. (Pubitemid 27050682)
44. Koch CJ, Shuman AL, Jenkins WT, Kachur AV, Karp JS, Freifelder R, et al. The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. Int J Radiat Biol 2009; 85: 1137-1147.
45. Dearling JLJ, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998; 25: 788-792. (Pubitemid 28377043)
46. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008; 49: 201-205. (Pubitemid 351225657)